Effect of ketanserin on platelet function and bleeding time in uremic patients treated with erythropoietin.
Malyszko
J
J
Nephrology Department, Medical School, Bialystok, Poland.
Pawlak
K
K
Borawski
J
J
Malyszko
J S
JS
Mysliwiec
M
M
D000328:Adult; D000740:Anemia / Q000188:drug therapy; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D016022:Case-Control Studies; D016903:Drug Monitoring; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007650:Ketanserin / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D010979:Platelet Function Tests; D006435:Renal Dialysis; D013927:Thrombosis / Q000139:chemically induced / Q000517:prevention & control; D014511:Uremia / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors; D004921:Erythropoietin; D007650:Ketanserin